Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics:

• All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00)
• Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21)
• First- and second-generation IDH inhibitors for AML (17:40)
• Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59)
• Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42)
• Novel combination approaches with menin inhibitors for AML (29:11)

CME information and select publications